Viral Hepatitis: Global Policy - selected data
Question Questions 1-10 In your country, is there a written national strategy… Q1.a. Exclusive for viral hepatitis Q1.b. only for hepatitis B Q1.d. Integrated with other diseases Q1.e. Do not know Q1.1. Raising awareness Q1.2. Surveil ance Q1.3. Vaccination Q1.4. Prevention in general Q1.5. prevention of transmission of viral hepatitis via i… Q1.6. Health care transmission prevention Q1.7. Treatment and Care Q1.8. Coinfection with HIV Is there a designated governmental unit/department re… Q2.a. If yes, how many staff members does it have Q2.b. Name of unit/department How many people work full-time on hepatitis-related a… Did your government hold events for World Hepatitis D… Has your government funded any public viral hepatitis… Q5.a. General information about hepatitis and its transmi Q5.b. Vaccination for hepatitis A and hepatitis B
Importance of knowing one’s hepatitis B and
Q5.d. Safe water and good sanitation Q5.e. Safer sex practices
Harm reduction for people who inject drugs
Q5.g. Safe workplace practices Q5.h. Other-please specify: Q5.h. Others specified: Does your government have a viral hepatitis preventio… Q6.a. Health workers (including health care waste handler Q6.a. Comment Q6.b. People who inject drugs Q6.b. Comment Q6.d. Prisoners Q6.e. The homeless Q6.g. Low-income populations Q6.h. The uninsured Does your government collaborate with any civil socie… Major partners specified Is there routine surveillance for viral hepatitis? Q9.a. Hepatitis A Q9.b. Hepatitis B Q9.d. Hepatitis D Q9.e. Hepatitis E Q10.a. Hepatitis B Q10.b. Hepatitis C Q10.c. Hepatitis D Questions 11-20 Do standard case definitions for hepatitis infection… A re deaths, including from hepatitis, reported to a … What percentage of hepatitis cases are reported as “… A re liver cancer cases registered? A re cases of HIV /hepatitis co-infection registered? Q16.a. weekly Q16.b. monthly Q16.c. annual y Q16.d. no reports published Q16.e. other Q16.e. Other listed A re hepatitis outbreaks reported? Q17.a. Are they further reported? Is there a national public health research agenda fo… A re viral hepatitis sero - surveys conducted regular… Q19.a. How often? Q19.b. When was the last one carried out? Q19.c.1.Children (please specify age group): ___________… Q19.c.1.Age group specified Q19.c.2.General population Q19.c.3.People who inject drugs Q19.c.4.Men who have sex with men Q19.c.5.Other groups Q19.c.5.other groups specified Is there adequate laboratory capacity nationally to … Q20.a. Hepatitis A Q20.b. Hepatitis B Q20.c. Hepatitis C Q20.d. Hepatitis E Questions 21-30 Is there a national hepatitis A vaccination Q21.a. Travel ers to highly endemic countries Q21.b. Military personnel Q21.c. Children, as part of the national routine vaccinat… Q21.d. Ecological and sanitary workers Q21.e. Other – please specify Q21.e. Others specified Has your government established the goal of eliminat… Q22.a. If yes, in what timeframe? Nationally, what percentage of newborn infants in a … Nationally, what percentage of one-year- olds (ages 1… Q25.Is. there a policy specifical y targetting MTCT of Hep… Q25.a. Al pregnant women are screened for hepatitis B Q25.b. Al pregnant women found to have hepatitis B are c Q25.c. Health care providers fol ow up with al pregnant … Q25.c. Comment Q25.d. Upon delivery, al infants born to women with hepa Q25.d. Comment Q25.e. Al infants receive the first dose of hepatitis B … Q25.e. Comment Q25.f. Al infants receive the second and third doses of … Q25.f. Comment Is there a specific national strategy and/or policy … Q26.a. Are health workers vaccinated against hepatitis B … Q26.a. Comment Is there a national policy on injection safety Q27.a.1.
What type of syringes does the policy recommend
Q27.a.2.
What type of syringes does the policy recommend
Q27.a.3.
What type of syringes does the policy recommend
A re single-use or auto-disable syringes, needles and… What are your government’s official Don't know estimates of the… Q29.a. Percentage (as a proportion of total injections ad… Is there a national infection control policy for Questions 31-40 A re all donated blood units (including family donati… A re all donated blood units (including family donati… Is there a national policy relating to the preventio… Does your government have guidelines addressing how … Q35.a. schools of health professionals (pre-service educa… Q35.b. on-the-job training Q35.c. Post-graduate training Q35.d. other: Q35.d. Other specified Q35.e. do not know Q36.a. Does your government have a national policy relati Q36.b. Does your government have a national policy relati Q37.1.a.
When testing, do people register by name (HepB)
Q37.1.b.
When testing, do people register by name (HepC)
Q37.1. Comment Q37.2.aI.f people register by name, are their names kept… Q37.2.bI.f people register by name, are their names kept… Q37.2. Comment Q37.3.aI.s the test free of charge for al individuals? … Q37.3.bI.s the test free of charge for al individuals? … Q37.3. Comment Q37.4.aI.s the test free of charge for members of any sp… Q37.4.a. Q37.4.bI.s the test free of charge for members of any sp… Q37.4.b. Q37.5.aI.s the test compulsory for members of any specif Q37.5.a. Q37.5.bI.s the test compulsory for members of any specif Q37.5.b. Q37.5. Comment A re there national clinical guidelines for the manag… Q38.a. If yes, do they include recommendations for cases Q38.b. If no, are there national clinical guidelines for … Is publicly funded treatment available for hepatitis… Q39.a. If yes, who is eligible for publicly funded treatm… Is publicly funded treatment available for hepatitis… Q40.a. If yes, who is eligible for publicly funded treatm… Questions 41-43 How much is spent by the government on publicly fund… Q42.a. at least one HepB treatment Q42.a.1I.nterferon alpha Q42.a.1. Q42.a.2. Q42.a.3.
Lamivudine (Epivir-HBV, Zeffix or Heptodin)
Q42.a.4. Q42.a.5. Q42.a.6. Q42.a.7. Q42.a.8. Q42.a.8. Q42.b. at least 1 HepC treatment Q42.b.1I.nterferon alpha Q42.b.1. Q42.b.2. Q42.b.3. Q42.b.4. Q42.b.5. Q42.b.6. Q42.b. Others listed Q43.a. Developing the national plan for viral hepatitis p… Q43.b. Viral hepatitis surveil ance Q43.c. Increasing coverage of the birth dose of the hepat Q43.d. Estimating the national burden of viral hepatitis Q43.e. Developing tools to assess the effectiveness of in… Q43.f. Increasing access to treatment Q43.g. Increasing access to diagnostics Q43.h. Improving laboratory quality Q43.i. Awareness-raising Q43.j. Developing education/training programmes for Q43.k. Assessing the economic impact of viral hepatitis Q43.l. Integrating viral hepatitis programmes into other … Q43.m.Other – please specify Q43.m.Others specified General.
Questions: Questions 1-10 Q1. In your country, is there a written national strategy or plan that focuses exclusively or primarily on the prevention and control of viral hepatitis?** Please e-mail us the relevant supporting information. Q1.a. Exclusive for viral hepatitis Q1.b. only for hepatitis B Q1.c. only for hepatitis C Q1.d. Integrated with other diseases Q1.e. Do not know Q1.1. Raising awareness Q1.2. Surveillance Q1.3. Vaccination Q1.4. Prevention in general Q1.5. prevention of transmission of viral hepatitis via injecting drug use Q1.6. Health care transmission prevention Q1.7. Treatment and Care Q1.8. Coinfection with HIV Q1. comment Q2. Is there a designated governmental unit/department responsible only for coordinating and/or carrying out viral hepatitis-related activities? Q2.a. If yes, how many staff members does it have Q2.b. Name of unit/department Q2. comment Q3. How many people work full-time on hepatitis-related activities in all government agencies/bodies? Q3. Comment Q4. Did your government hold events for World Hepatitis Day 2012?* Q4. Comment Q5. Has your government funded any public viral hepatitis awareness campaigns since January 2011, other than World Hepatitis Day?* Q5.a. General information about hepatitis and its transmission Q5.b. Vaccination for hepatitis A and hepatitis B Q5.c. Importance of knowing one’s hepatitis B and hepatitis C status Q5.d. Safe water and good sanitation Q5.e. Safer sex practices Q5.f. Harm reduction for people who inject drugs Q5.g. Safe workplace practices Q5.h. Other-please specify: Q5.h. Others specified: Q5. Comment Q6. Does your government have a viral hepatitis prevention and control program that includes activities targetting specific populations? Q6. Comment Q6.a. Health workers (including health care waste handlers) Q6.a. Comment Q6.b. People who inject drugs Q6.b. Comment Q6.c. Migrants Q6.d. Prisoners Q6.e. The homeless Q6.f. People living with HIV Q6.g. Low-income populations Q6.h. The uninsured Q6.i. Indigenous people Q6.j. Other Q6.j. Other- please specify Q7. Does your government collaborate with any civil society groups within your country (such as patient groups or national or local nongovernmental organisations) to develop and implement its viral hepatitis prevention and control programme? If yes, please name major partners. Q7. Major partners specified Q7. Comment Q8. Is there routine surveillance for viral hepatitis? Q9.a. Hepatitis A Q9.b. Hepatitis B Q9.c. Hepatitis C Q9.d. Hepatitis D Q9.e. Hepatitis E Q9. comment Q10.a. Hepatitis B Q10.b. Hepatitis C Q10.c. Hepatitis D Questions 11-20 Q11. Do standard case definitions for hepatitis infections exist? Q11. Comment Q12. A re deaths, including from hepatitis, reported to a central registry? Q12. Comment Q13. What percentage of hepatitis cases are reported as “undifferentiated” or “unclassified” hepatitis? Q13. Comment Q14. A re liver cancer cases registered? Q14. Comment Q15. A re cases of HIV /hepatitis co-infection registered? Q15. Comment Q16.a. weekly Q16.b. monthly Q16.c. annually Q16.d. no reports published Q16.e. other Q16.e. Other listed Q16. Comment Q17. A re hepatitis outbreaks reported? Q17.a. A re they further reported? Q17. comment Q18. Is there a national public health research agenda for viral hepatitis?* Q18. Comment Q19. A re viral hepatitis sero - surveys conducted regularly? Q19. Comment Q19.a. How often? Q19.b. When was the last one carried out? Q19.c.1. Children (please specify age group): ______________________ Q19.c.1 A ge group specified Q19.c.2. General population Q19.c.3. People who inject drugs Q19.c.4 Men who have sex with men Q.19.c.5. Other groups Q.19.c.5. other groups specified Q20. Is there adequate laboratory capacity nationally to support viral hepatitis outbreak investigations and other surveillance activities? Q20.a. Hepatitis A Q20.b. Hepatitis B Q20.c. Hepatitis C Q20.d. Hepatitis E Q20. Comment Questions 21-30 Q21. Is there a national hepatitis A vaccination policy? Q21. Comment Q21.a. Travellers to highly endemic countries Q21.b. Military personnel Q21.c. Children, as part of the national routine vaccination program Q21.d. Ecological and sanitary workers Q21.e. Other – please specify Q21.e. Others specified Q22. Has your government established the goal of eliminating hepatitis B? Q22.a. If yes, in what timeframe? Q22. Comment Q23. Nationally, what percentage of newborn infants in a given recent year received the first dose of hepatitis B vaccine within 24 hours of birth? Q23. Comment Q24. Nationally, what percentage of one-year-olds (ages 12-23 months) in a given recent year received three doses of hepatitis B vaccine? Q24. Comment Q25.Is there a policy specifically targetting MTCT of HepB? Q25. Comment Q25.a. A ll pregnant women are screened for hepatitis B Q25.b. A ll pregnant women found to have hepatitis B are counselled Q25.c. Health care providers follow up with all pregnant women found to have hepatitis B during pregnancy for the purpose of encouraging them to give birth at health care facilities Q25.c. Comment Q25.d. Upon delivery, all infants born to women with hepatitis B receive hepatitis B immunoglobulin Q25.d. Comment Q25.e. A ll infants receive the first dose of hepatitis B vaccine within 24 hours of birth Q25.e. Comment Q25.f. A ll infants receive the second and third doses of hepatitis B vaccine within 12 months of birth Q25.f comment Q26. Is there a specific national strategy and/or policy for preventing hepatitis B and hepatitis C infection in healthcare settings? Q26. comment Q26.a. A re health workers vaccinated against hepatitis B prior to starting work that might put them at risk of exposure to blood? Q26.a. Comment Q27. Is there a national policy on injection safety in health care settings? Q27. comment Q27.a.1. What type of syringes does the policy recommend for therapeutic injections? (single-use syringes) Q27.a.2. What type of syringes does the policy recommend for therapeutic injections? (auto-disable syringes) Q27.a.3. What type of syringes does the policy recommend for therapeutic injections? (do not know) Q28. A re single-use or auto-disable syringes, needles and cannulas always available in all healthcare facilities? Q28. Comment Q29. What are your government’s official estimates of the number of unnecessary injections administered annually in health care settings? (e.g., injections that are given when an equivalent oral medication is available) Q29. comment Q29.a. Percentage (as a proportion of total injections administered annually in health care settings) Q30. Is there a national infection control policy for blood banks?* Q30. Comment Questions 31-40 Q31. A re all donated blood units (including family donations) and blood products nationwide screened for hepatitis B? Q32. A re all donated blood units (including family donations) and blood products nationwide screened for hepatitis C? Q33. Is there a national policy relating to the prevention of viral hepatitis among people who inject drugs?* Q33. Comment Q34. Does your government have guidelines addressing how hepatitis A and hepatitis E can be prevented through food and water safety? Q34. Comment Q35.a. schools of health professionals (pre-service education) Q35.b. on-the-job training Q35.c. Post-graduate training Q35.d. other: Q35.d. Other specified Q.35.e. do not know Q36.a. Does your government have a national policy relating to screening and referral to care for Hepatitis B?* Q36.b. Does your government have a national policy relating to screening and referral to care for Hepatitis C?* Q36. Comment Q37.1.a. When testing, do people register by name (HepB) Q37.1.b. When testing, do people register by name (HepC) Q37.1. Comment Q37.2.a. If people register by name, are their names kept confidential within the system, or is there open access? (HepB) Q37.2.b. If people register by name, are their names kept confidential within the system, or is there open access? (HepC) Q.37.2. Comment Q37.3.a. Is the test free of charge for all individuals? (HepB) Q37.3.b. Is the test free of charge for all individuals? (HepC) Q37.3. Comment Q37.4.a. Is the test free of charge for members of any specific groups? (HepB) Q37.4.a. Groups specified Q37.4.b. Is the test free of charge for members of any specific groups? (HepC) Q37.4.b. Groups specified Q37.5.a. Is the test compulsory for members of any specific groups? (Hep B) Q37.5.a. Groups specified Q37.5.b. Is the test compulsory for members of any specific groups? (HepC) Q37.5.b. Groups specified Q37.5. Comment Q38. A re there national clinical guidelines for the management of viral hepatitis?* Q38.a. If yes, do they include recommendations for cases of HIV co-infection? Q38.b. If no, are there national clinical guidelines for the management of HIV that include recommendations for coinfection with viral hepatitis? Q38. comment Q39. Is publicly funded treatment available for hepatitis B? Q39.a. If yes, who is eligible for publicly funded treatment for hepatitis B? Please specify: Q39. comment Q40. Is publicly funded treatment available for hepatitis C? Q40.a. If yes, who is eligible for publicly funded treatment for hepatitis C? Please specify: Q40. Comment Questions 41-43 Q41. How much is spent by the government on publicly funded treatment for hepatitis B and hepatitis C? (Please indicate currency. Please also indicate whether the amount is for one or both of the infections.) Q41. Comment Q42.a. at least one HepB treatment Q42.a.1. Interferon alpha Q42.a.1. Comment Q42.a.2. Pegylated interferon Q42.a.3. Lamivudine (Epivir-HBV, Zeffix or Heptodin) Q42.a.4. A defovir dipivoxil (Hepsera) Q42.a.5. Entecavir (Baraclude) Q42.a.6. Telbivudine (Tyzeka, Sebivo) Q42.a.7. Tenofovir (V iread) Q42.a.8. Other Q42.a.8. Others listed Q42.b. at least 1 HepC treatment Q42.b.1. Interferon alpha Q42.b.1. Comment Q42.b.2. Pegylated interferon Q42.b.3. Ribavirin Q42.b.4. Boceprevir (V ictrelis) Q42.b.5. Telaprevir (Incivo, Incivek) Q42.b.6. Other: Q42.b. Others listed Q42. Comment Q43.a. Developing the national plan for viral hepatitis prevention and control Q43.b. V iral hepatitis surveillance Q43.c. Increasing coverage of the birth dose of the hepatitis B vaccine Q43.d. Estimating the national burden of viral hepatitis Q43.e. Developing tools to assess the effectiveness of interventions Q43.f. Increasing access to treatment Q43.g. Increasing access to diagnostics Q43.h. Improving laboratory quality Q43.i. A wareness-raising Q43.j. Developing education/training programmes for health professionals Q43.k. A ssessing the economic impact of viral hepatitis Q43.l. Integrating viral hepatitis programmes into other health services Q43.m. Other – please specify Q43.m. Others specified General comments
September 2012 CVS Caremark Value Priced Generics List The CVS Caremark Value Priced Generics Drug List offers Capital Health Plan members access to a 30-day supply of select maintenance generic medications under the member's prescription benefit plan and can be fil ed at any retail store in the pharmacy network. Capital Health Plan members may receive a 90-day supply from a particip
11th NAPRECA Symposium Book of Proceedings, Antananarivo, Madagascar Natural Products and Drug Discovery through a Network of Partnerships Philippe Rasoanaivo, David Ramanitrahasimbola, Dina Rakotondramanana, Voahangy Ramanandraibe, Suzanne Ratsimamanga Institut Malgache de Recherches Appliquées Abstract We present here relevant result obtained from a network of collaborations. Mala